{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:08:30Z","timestamp":1793023710087,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Finerenone reduces albuminuria and improves kidney outcomes in patients with diabetic kidney disease (DKD); however, its association with changes in non-albumin proteinuria (NAP), enriched for tubular injury-related proteins, remains unclear. We evaluated whether finerenone treatment was associated with a reduction in NAP and identified clinical phenotypes associated with a greater NAP response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 477 patients treated with finerenone who had baseline urine albumin-to-creatinine ratio (uACR) and urine protein-to-creatinine ratio (uPCR) measurements from the same urine specimen. Urine non-albumin protein-to-creatinine ratio (uNAPCR) was calculated as uPCR minus uACR. Patients were stratified by baseline proteinuria severity (uPCR &amp;lt; 500 vs \u2265 500 mg\/gCr). The primary outcome was the geometric mean percentage change in uNAPCR after 6 months of finerenone treatment, assessed using linear mixed-effects models. Subgroup interaction analyses were performed to assess differential associations and identify factors associated with greater uNAPCR reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, median uPCR, uACR, and uNAPCR were 1140 [580, 2290], 716 [328, 1593], and 410 [223, 700] mg\/gCr, respectively. At 6 months, uACR and uNAPCR declined by 30.3% and 17.5%, respectively. Subgroup analyses revealed differential associations: patients with higher baseline proteinuria (uPCR \u2265 500 mg\/gCr) showed an 18.8% decline in uNAPCR, whereas those with uPCR &amp;lt; 500 mg\/gCr showed a non-significant 1.3% change. Changes in uNAPCR were positively correlated with changes in urine N-acetyl-\u03b2-D-glucosaminidase-to-creatinine ratio (uNAGCR) (Spearman\u2019s \u03c1 = 0.53; p &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Finerenone treatment was associated with a reduction in NAP, particularly among patients with higher baseline proteinuria, suggesting a possible effect on tubulointerstitial injury-related processes beyond albuminuria reduction. Prospective multicenter studies are needed to validate uNAPCR as a treatment-response biomarker against clinical endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1918192","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:00Z","timestamp":1788841560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-albumin proteinuria as a candidate biomarker of treatment response to finerenone in diabetic kidney disease: a real-world cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Min Seo","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minheui","family":"Yu","sequence":"additional","affiliation":[{"name":"SENTINEL Team, Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12916-021-02050-0","article-title":"Recent advances in diabetic kidney disease","volume":"19","author":"Hanouneh","year":"2021","journal-title":"BMC Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050752","article-title":"Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk","volume":"13","author":"Scilletta","year":"2023","journal-title":"Biomolecules"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2546","article-title":"Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients","volume":"30","author":"Kim","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.04.014","article-title":"Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria","volume":"33","author":"Cho","year":"2019","journal-title":"J Diabetes Complications"},{"key":"B6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13098-017-0267-4","article-title":"Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression","volume":"9","author":"Kim","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1038\/s41598-024-61395-7","article-title":"Urinary non-albumin protein-creatinine ratio is an independent predictor of mortality in patients with type 2 diabetes: a retrospective cohort study","volume":"14","author":"Cheng","year":"2024","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by finerenone\u2014translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"B12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent antifibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist, protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000524940","article-title":"Finerenone reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage","volume":"53","author":"Luettges","year":"2022","journal-title":"Am J Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/life11030224","article-title":"Non-albumin proteinuria (NAP) as a complementary marker for diabetic kidney disease (DKD)","volume":"11","author":"Bae","year":"2021","journal-title":"Life (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03083.x","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril","volume":"27","author":"Nielsen","year":"2010","journal-title":"Diabetes Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00557.2010","article-title":"Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney","volume":"301","author":"Irita","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000543923","article-title":"Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the USA: a cohort study from the FOUNTAIN platform","volume":"149","author":"Kovesdy","year":"2025","journal-title":"Nephron"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-02070-y","article-title":"First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting","volume":"37","author":"Nicholas","year":"2024","journal-title":"J Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1918192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:02Z","timestamp":1788841562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1918192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":29,"alternative-id":["10.3389\/fendo.2026.1918192"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1918192","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1918192"}}